Perspectives: Treating Depression in Dialysis Patients





Today's Presenters



Derek Forfang

Patient Subject Matter Expert, ESRD Network 17

Raj Mehrotra, MD, MS

Head, Division of Nephrology, University of Washington

Renee Bova-Collis, MSW, LCSW

Patient Engagement Specialist, Quality Insights Renal Network 5

Patrick Gee, PhD, JLC

Patient Subject Matter Expert, ESRD Network 5

Lisa Custer

Patient Subject Matter Expert, ESRD Network 16

The Patient Perspective



Derek Forfang
Patient Subject Matter Expert
ESRD Network 17



Depression in Dialysis: A Family in Crisis









The Research



Raj Mehrotra, MD, MS
Head, Division of Nephrology,
University of Washington
Principal Investigator,
The ASCEND Study



Disclosures



- Consultant, Lightline Medical
- Editor-in-Chief, Clinical Journal of the American Society of Nephrology
- Chair, Board of Trustees, Northwest Kidney Centers
- Chair, Approval Committee, Longitudinal Knowledge Assessment,
 American Board of Internal Medicine

Depression is Common with Dialysis Therapy




No. of cohorts	No. of participants	Prevalence of clinical depression Random effects (95% CI)		depres Random	ssion effects	l	sub	value for group erence	
134	36,369	38.5% (35.4–41.6)		Þ				0.70	
35	2796	37.3% (31.7–43.5)						0.73	
ion									
28	2855	22.8% (18.6–27.6)		-					
23	3967	31.3% (25.5–37.6)		-					
8	10,561	40.6% (30.5–51.6)		-	-	.0.001		-0.001	
87	9384	41.3% (37.9–44.7)					<0.00		
9	592	46.9% (36.0–58.2)		⊢ ■	—				
4	354	55.0% (39.1–70.0)		-	-				
198	46.505	36.8% (34.4–39.2)							
	•	/- (5 3 3.2)							
•				 		Т			
			0	20 40	60	80	100		
	cohorts 134 35 sion 28 23 8 87 9 4	cohorts participants 134 36,369 35 2796 sion 28 2855 23 3967 8 10,561 87 9384 9 592 4 354	No. of cohorts No. of participants Clinical depression Random effects (95% CI) 134 36,369 38.5% (35.4–41.6) 35 2796 37.3% (31.7–43.5) sion 28 2855 22.8% (18.6–27.6) 23 3967 31.3% (25.5–37.6) 8 10,561 40.6% (30.5–51.6) 87 9384 41.3% (37.9–44.7) 9 592 46.9% (36.0–58.2) 4 354 55.0% (39.1–70.0)	No. of cohorts Participants Clinical depression Random effects (95% CI) 134	No. of cohorts participants (95% CI) depression Random effects (95% CI) (95% CI) 134 36,369 38.5% (35.4–41.6) 35 2796 37.3% (31.7–43.5) sion 28 2855 22.8% (18.6–27.6) 23 3967 31.3% (25.5–37.6) 8 10,561 40.6% (30.5–51.6) 87 9384 41.3% (37.9–44.7) 9 592 46.9% (36.0–58.2) 4 354 55.0% (39.1–70.0)	No. of cohorts No. of participants Random effects (95% CI) 134 36,369 38.5% (35.4–41.6) 35 2796 37.3% (31.7–43.5) 28 2855 22.8% (18.6–27.6) 23 3967 31.3% (25.5–37.6) 8 10,561 40.6% (30.5–51.6) 87 9384 41.3% (37.9–44.7) 9 592 46.9% (36.0–58.2) 4 354 55.0% (39.1–70.0) 198 46,505 36.8% (34.4–39.2)	No. of cohorts	No. of cohorts No. of participants Clinical depression Random effects (95% CI) Random effects (95% CI) Subdiffer	

One in every three patients has significant depressive symptoms

Even more common during stress – hurricanes, pandemics

Depression Has Far-reaching Consequences






Depression Does Not Just Go Away



Monthly Assessments



Without treatment, people's mood generally remains the same month after month

PCORI-Funded Study for Treatment



Annals of Internal Medicine

ORIGINAL RESEARCH

Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis

A Randomized Clinical Trial

Rajnish Mehrotra, MD, MS; Daniel Cukor, PhD; Mark Unruh, MD, MS; Tessa Rue, MS; Patrick Heagerty, MS, PhD; Scott D. Cohen, MD, MPH; Laura M. Dember, MD; Yaminette Diaz-Linhart, MSW, MPH; Amelia Dubovsky, MD; Tom Greene, PhD; Nancy Grote, MSW, MEd, PhD; Nancy Kutner, PhD; Madhukar H. Trivedi, MD; Davin K. Quinn, MD; Nisha ver Halen, PhD; Steven D. Weisbord, MD, MSc; Bessie A. Young, MD, MPH; Paul L. Kimmel, MD; and S. Susan Hedayati, MD, MSc





ASCEND:Two Goals



In people undergoing hemodialysis, with a diagnosis of depression (major depressive disorder or dysthymia):

- An engagement interview increases the acceptance of treatment for depression and
- There is significant difference in the efficacy of 12 weeks of treatment with cognitive behavioral therapy and sertraline drug therapy





Who Did We Enroll in the Study?



Inclusion Criteria

- 1. Age \geq 21 years
- Undergoing thrice weekly in-center HD ≥
 3 months
- 3. Able to speak English or Spanish
- 4. Beck Depression Inventory score ≥ 15
- 5. Meets diagnostic criteria for current major depressive episode or dysthymia on MINI

Key Exclusion Criteria (of 13)


- 1. Active suicidal intent
- 2. Intensive psychotherapy for treating depression
- 3. Current drug therapy with SSRI or SNRI at doses higher than minimally effective
- 4. Present or past psychosis on MINI
- Alcohol or substance abuse on MINI or history in past 3 months





Enrollment of Study Participants for Phase I





Engagement interview did not work


- Engagement interview, 66%
- Control visit, 64%





How Was Treatment Given?





<u>Cognitive behavioral therapy</u>: Therapists drove from one unit to another to deliver face-to-face therapy to patients when they were dialyzing or after HD session

10 sessions scheduled over 12 weeks; 80% completed at least 8 sessions


Sertraline drug therapy: We started at 25 mg dose, increased to 50 mg in the second week. From third week onwards, dose could be increased by 50 mg every 2 weeks, if patient did not have side effects, max 200 mg.

Median dose at 12 weeks, 150 mg; 78% still taking medication at 12 weeks



What Happened with Treatment?





- Depressive symptoms got better with both
 - Magnitude of change was clinically meaningful
- Improvement with sertraline was slightly larger than with CBT:
 - Difference in effect with two treatments was not meaningful
- Both treatments worked





Were There Any Side Effects?



Adverse Events	Events, n		Patients With Any Event, n (%)		Rate Difference Between Sertraline and CBT (95% CI)	
	СВТ	Sertraline	CBT (n = 60)	Sertraline (n = 60)		
Serious						
Total	13	18	11 (18)	14 (23)	0.08 (-0.11 to 0.28)	
Death	2	0	2 (3)	0 (0)	-0.03 (-0.08 to 0.01)	
Hospitalization/other	11	18	9 (15)	14 (23)	0.12 (-0.07 to 0.31)	
Major bleeding	1	2	1 (2)	2 (3)	0.02 (-0.04 to 0.07)	
Cardiac	4	4	3 (5)	4 (7)	0 (-0.10 to 0.10)	
Gastrointestinal	1	1	1 (2)	1 (2)	0 (-0.05 to 0.05)	
Infection	3	2	2 (3)	2 (3)	-0.02 (-0.10 to 0.07)	
Other	2	9	2 (3)	8 (13)	0.12 (0.01 to 0.23)	
Other						
Total	17	56	12 (20)	25 (42)	0.65 (0.25 to 1.05)	
Gastrointestinal	11	22	7 (12)	15 (25)	0.18 (-0.04 to 0.40)	
Cardiac	3	9	3 (5)	8 (13)	0.10 (-0.02 to 0.22)	
Nervous system	0	8	0 (0)	6 (10)	0.13 (0.02 to 0.25)	
Other	3	17	3 (5)	14 (23)	0.23 (0.08 to 0.38)	






Key Messages



- 1. Depression is common in people on dialysis
- 2. People either want treatment or they don't! Engagement interview did not work
- 3. It is possible to provide high-quality treatment in the dialysis unit, without the need to refer to outside specialist
- 4. High-level of adherence with both CBT and sertraline drug therapy
- 5. Depressive symptoms improved similarly with both treatments
- 6. Mild-to-moderate side effects were more common with sertraline than with CBT








The Network Statement of Work



Renée Bova-Collis, MSW, LCSW
Patient Engagement Specialist,
Quality Insights Renal Network 5



Network Focus on Behavioral Health



- CMS-directed Statement of Work
 - Increase in percent of patients receiving/having received treatment by a mental health professional after screening positive for depression
- Known Barriers
 - Reporting of screenings in EQRS
 - Availability of/accessibility to mental health professionals
 - Stigma

Depression Screening Tools



- ESRD Medicare Conditions for Coverage
 - 494.90 Patient Plan of Care(a)(6)
 - "The interdisciplinary team must provide the necessary monitoring and social work interventions. These
 include counseling services and referrals for other social services, to assist the patient in achieving and
 sustaining an appropriate psychosocial status as measured by a standardized mental and physical
 assessment tool chosen by the social worker, at regular intervals, or more frequently on an as-needed
 basis."
- Beck Depression Inventory (BDI)
- Center for Epidemiologic Studies Depression Scale (CES-D)
- EQ-5D
- Hamilton Depression Rating Scale (HAM-D)
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR)
- Patient Health Questionnaire (PHQ-9)
- Children's Depression Inventory (CDI)
- Children's Depression Rating Scale (CDRS)
- Geriatric Depression Scale (GDS)

21

Treatment Referral



- Community Services Boards (CSB)
- Hospitals with psychiatric services
- Primary Care Physicians
- More frequent dialysis options
- Normalize it

The American Academy of Family Physicians Foundation's Neighborhood Navigator: https://navigator.aafp.org/

Primary Care Behavioral Health (PCBH) Model:

https://psychologyinterns.org/wpcontent/uploads/Reiter2018 Article ThePrimaryCareBehavioralHealth.pdf

Implicit Bias



- Impact on screening and referral
 - Behavior towards others
 - Distrust
 - Denial
 - Avoidance
- Strategies to address
 - Be aware of your biases and act on them
 - Implicit Association Test https://implicit.harvard.edu/implicit/takeatest.html
 - Learn about and value diverse peoples
 - Identify appropriate services
 - Create a safe environment
 - Mirror staff with the populations/communities served
 - Check out this guide: <u>https://www.aafp.org/dam/AAFP/documents/patient_care/everyone_project/team-based-approach.pdf</u>

The Patient Perspective





Patrick Gee, PhD, JLC
Patient Subject Matter Expert
ESRD Network 5

Lisa Custer
Patient Subject Matter Expert
ESRD Network 16



Resources



PCORI Evidence Updates:

- Cognitive Behavioral Therapy vs. Sertraline for Depression in Patients with Kidney Failure Receiving Hemodialysis (for Providers):
 - https://www.pcori.org/sites/default/files/PCORI-Evidence-Update-for-Clinicians-CBT-vs-Sertraline-for-Depression-in-Patients-Receiving-
 - Hemodialysis.pdf?utm_source=partner&utm_medium=email&utm_campaign=The+National+Forum+of+ESRD+Networks
- Treating Depression When You're on Dialysis (for Patients):

 https://www.pcori.org/sites/default/files/PCORI-Evidence-Update-for-Patients-Treating-Depression-When-Youre-on-Dialysis.pdf?utm source=partner&utm medium=email&utm campaign=The+National+Forum+of+ESRD+Networks

Project Web Page - Depression in Dialysis Patients:

https://esrdnetworks.org/education/depression-in-dialysis-patients/

Podcast:

Depression and Dialysis – Reviewing the ASCEND Study https://www.kidney.org/podcasts/kidney-commute

Kidney Patient Advisory Committee Dialysis Patient Depression Toolkit:

https://esrdnetworks.org/toolkits/patient-toolkits/dialysis-patient-depression-toolkit/

If you have additional questions or want more resources, please visit the Forum website at

https://esrdnetworks.org/education/depression-in-dialysis-patients/ or contact the Forum:

> Kelly Brooks, MPA, Coordinator National Forum of ESRD Networks Phone: 804-390-9822

kbrooks@esrdnetworks.org

